Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

New England Journal of Medicine

Volumn 373, Issue 25, 2015, Pages 2425-2437

  Burger, J A ^a   Tedeschi, A ^b   Barr, P M ^e   Robak, T ^f   Owen, C ⁱ   Ghia, P ^c   Bairey, O ^j   Hillmen, P ^l   Bartlett, N L ^p   Li, J ^q   Simpson, D ^r   Grosicki, S ^g   Devereux, S ^m   McCarthy, H ⁿ   Coutre, S ^s   Quach, H ^w   Gaidano, G ^d   Maslyak, Z ^y   Stevens, D A ^z   Janssens, A ^aa   Offner, F ^ab   Mayer, J ^ac   O'Dwyer, M ^ad   Hellmann, A ^h   Schuh, A ^o   Siddiqi, T ^t   Polliack, A ^k   Tam, C S ^x   Suri, D ^u   Cheng, M ^u   Clow, F ^u   Styles, L ^u   James, D F ^u   Kipps, T J ^v   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

^g MEDICAL UNIVERSITY OF SILESIA   (Poland)

^h MEDICAL UNIVERSITY OF GDANSK   (Poland)

ⁱ TOM BAKER CANCER CENTRE   (Canada)

^j TEL AVIV UNIVERSITY   (Israel)

^k HEBREW UNIVERSITY   (Israel)

^l LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^m KING S COLLEGE HOSPITAL   (United Kingdom)

ⁿ ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^o UNIVERSITY OF OXFORD   (United Kingdom)

^p WASHINGTON UNIVERSITY   (United States)

^q THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^r NORTH SHORE HOSPITAL   (New Zealand)

^s STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^t CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^u PHARMACYCLICS INC   (United States)

^v UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^w UNIVERSITY OF MELBOURNE   (Australia)

^x ST VINCENT S HOSPITAL   (Australia)

^y STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

^z Norton Cancer Institute   (United States)

^aa UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^ab GHENT UNIVERSITY HOSPITAL   (Belgium)

^ac UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^ad UNIVERSITY HOSPITAL GALWAY   (Ireland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; HEMOGLOBIN; IBRUTINIB; ANTINEOPLASTIC AGENT; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ABDOMINAL PAIN; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ATRIAL FIBRILLATION; BASAL CELL CARCINOMA; BLEEDING; CANCER GROWTH; CANCER RISK; CAUSE OF DEATH; CELLULITIS; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRY EYE; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HUMAN; HYPERTENSION; HYPONATREMIA; INTRAPARENCHYMAL HEMORRHAGE; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SUBDURAL HEMATOMA; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MORTALITY; PHASE 3 CLINICAL TRIAL; SURVIVAL;

AGED; ANTINEOPLASTIC AGENTS; CHLORAMBUCIL; DIARRHEA; DISEASE-FREE SURVIVAL; FATIGUE; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; NEUTROPENIA; PYRAZOLES; PYRIMIDINES; SURVIVAL ANALYSIS;

EID: 84950133717     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1509388     Document Type: Article

References (39)

1. Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22: Suppl6: vi50-vi54.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
3. Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009; 114: 3382-91.
4. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 5616-23.
5. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 4378-84.
6. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750-7.
7. Woyach JA, Ruppert AS, Rai K, et al. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential Cancer and Leukemia Group B studies. J Clin Oncol 2013; 31: 440-7.
8. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 2007; 370: 230-9.
9. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370: 1101-10.
10. Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): A randomised, multicentre, open-label phase 3 trial. Lancet 2015; 385: 1873-83.
11. Goede V, Fischer K, Engelke A, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia 2015; 29: 1602-4.
12. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-74.
13. Eichhorst B, Fink A-M, Busch R, et al. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus bendamustine and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a planned interim analysis of the CLL10 trial, an international, randomized study of the German CLL Study Group (GCLLSG). Blood 2013; 122: 526. abstract.
14. Casak SJ, Lemery SJ, Shen YL, et al. U.S. Food and Drug Administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia. Oncologist 2011; 16: 97-104.
15. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975-80.
16. Imbruvica prescribing information. Sunnyvale, CA: Pharmacyclics, May 2015 (https://www.janssenmd.com/pdf/imbruvica/PI-Imbruvica.pdf).
17. Imbruvica summary of product characteristics. London: European Medicines Agency, October 2014 (http://ec.europa.eu/health/documents/community-register/2014/20141021129815/anx-129815-en.pdf).
18. de Gorter DJ, Beuling EA, Kersseboom R, et al. Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 2007; 26: 93-104.
19. de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI- 32765 targets B-cell receptor- And chemokine- controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012; 119: 2590-4.
20. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011; 117: 6287-96.
21. Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI- 32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012; 119: 1182-9.
22. Spaargaren M, Beuling EA, Rurup ML, et al. The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J Exp Med 2003; 198: 1539- 50.
23. Burger JA, Li K, Keating M, et al. Functional evidence from deuterated water labeling that the Bruton tyrosine kinase inhibitor ibrutinib blocks leukemia cell proliferation and trafficking and promotes leukemia cell death in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Blood 2014; 124: 326. abstract.
24. Herman SE, Mustafa RZ, Gyamfi JA, et al. Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood 2014; 123: 3286-95.
25. Herman SE, Niemann CU, Farooqui M, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia 2014; 28: 2188-96.
26. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213-23.
27. Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 2015; 125: 2497-506.
28. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute Working Group 1996 guidelines. Blood 2008; 111: 5446-56.
29. Hallek M, Cheson BD, Catovsky D, et al. Response assessment in chronic lymphocytic leukemia treated with novel agents causing an increase of peripheral blood lymphocytes. Blood 2012 June 4 (http://www.bloodjournal.org/content/111/12/5446.e-letters).
30. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Bethesda, MD: National Institutes of Health 2010 (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf).
31. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphoma version 1.2015. Fort Washington, PA: National Comprehensive Cancer Network, 2015 (www.nccn.org/professionals/physician-gls/pdf/nhl.pdf).
32. Farooqui MZ, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: A phase 2, single-arm trial. Lancet Oncol 2015; 16: 169-76.
33. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152: 714-26.
34. Stilgenbauer S, Sander S, Bullinger L, et al. Clonal evolution in chronic lymphocytic leukemia: Acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007; 92: 1242-5.
35. Jethwa A, Hullein J, Stolz T, et al. Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia. Br J Haematol 2013; 163: 496-500.
36. Benjamini O, Jain P, Trinh L, et al. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma 2015; 56: 1643-50.
37. Morrison VA, Rai KR, Peterson BL, et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, Cancer and Leukemia Group B 9011. J Clin Oncol 2002; 20: 3878-84.
38. Ghielmini M, Vitolo U, Kimby E, et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). Ann Oncol 2013; 24: 561- 76.
39. Gribben JG. How I treat CLL up front. Blood 2010; 115: 187-97.